Sign In
Buy RNA
$11.35
-0.110 (-0.96%)
At Close: Jul 31, 2026
-- Unprecedented improvement compared to baseline and natural history in multiple functional measures including Time to Rise from Floor (TTR), 4-Stair Climb (4SC), Performance of Upper Limb (PUL) and
Avidity Biosciences, Inc. (RNA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
04:45pm, Monday, 08'th Sep 2025
Avidity Biosciences, Inc. (NASDAQ:RNA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:50 PM EDT Company Participants Kathleen Gallagher - Chief Program Officer Michael Ma
Avidity Biosciences, Inc. (RNA) Presents At Cantor Global Healthcare Conference 2025 Transcript
10:15pm, Sunday, 07'th Sep 2025
Avidity Biosciences, Inc. (NASDAQ:RNA ) Cantor Global Healthcare Conference 2025 September 3, 2025 10:20 AM EDT Company Participants Sarah Boyce - President, CEO & Director Steven Hughes - Chief Medic
Avidity Biosciences, Inc. (RNA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
05:37am, Friday, 05'th Sep 2025
Avidity Biosciences, Inc. (NASDAQ:RNA ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Michael MacLean - Chief Financial Officer Kathleen Gallag
RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?
03:26pm, Monday, 25'th Aug 2025
Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.
Avidity (RNA) Q2 Revenue Jumps 88%
06:19pm, Thursday, 07'th Aug 2025
Avidity (RNA) Q2 Revenue Jumps 88%
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights
04:05pm, Thursday, 07'th Aug 2025
Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE™ trial, and initiated global confirmatory Phase 3 study Planned
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal
12:46pm, Wednesday, 06'th Aug 2025
Avidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech company.
Novartis weighs deal for biotech Avidity Biosciences, FT reports
11:41am, Wednesday, 06'th Aug 2025
Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported, citing people familiar with the matter
-- Topline data readout from HARBOR study anticipated in Q2 2026 -- -- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated to start in H2 2026; on track to p
-- On track for planned BLA submission for del-zota at year end 2025 -- SAN DIEGO , July 23, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to del
-- FDA alignment on accelerated and full approval pathways for delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) -- -- Jeffrey M. Statland, M.D.
-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and sign
-- Planning accelerated approval BLA submission in H2 2026, following topline data fromFORTITUDE™ biomarker cohort in Q2 2026 -- -- Initiated global, confirmatory Phase 3 FORWARD ™ study of del-br
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 21'st May 2025
SAN DIEGO , May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co
